Bone Morphogenic Protein (bmp) Or Derivative Patents (Class 514/8.8)
-
Publication number: 20140356378Abstract: Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicant: GENERA ISTRAZIVANJA d.o.oInventors: Slobodan VUKICEVIC, Lovorka GRGUREVIC, Boris MACEK
-
Publication number: 20140356814Abstract: The present invention relates to a dental implant having an enhanced early stability and a method for manufacturing same, and more specifically to a dental implant and a method for manufacturing same which assure early stability and fixation power of an implant by suppressing early osteolysis after an implant procedure, and allowing better bone coherence of the implant surface during an osteogenic period by controlling the speed of bone remodeling.Type: ApplicationFiled: October 4, 2012Publication date: December 4, 2014Inventors: Su Kyoung Kim, Eun Jung Kang, Ju Dong Song, Tae Gwan Eom, Kyoo Ok Choi
-
Patent number: 8900633Abstract: The invention concerns a method for the production of a product having a polymer matrix, products which can be produced in accordance therewith and the use thereof.Type: GrantFiled: December 19, 2007Date of Patent: December 2, 2014Inventors: Herbert Jennissen, Maria Chatzinikolaidou
-
Patent number: 8895506Abstract: The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.Type: GrantFiled: March 7, 2013Date of Patent: November 25, 2014Assignee: DePuy Synthes Products, LLCInventors: Venkata R. Garigapati, Dongling Su, Rehan Khanzada, Steven J. Sawamura
-
Publication number: 20140342976Abstract: The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-? superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.Type: ApplicationFiled: March 17, 2014Publication date: November 20, 2014Applicant: Stryker CorporationInventors: Mary Elizabeth Pecquet Goad, Denis Schrier, Allen Richard Pierce
-
Publication number: 20140341964Abstract: Described is an implantable medical material comprising a malleable, cohesive, shape-retaining putty including mineral particles, insoluble collagen fibers and soluble collagen. The medical material can be used in conjunction with biologically active factors such as osteogenic proteins to treat bone or other tissue defects in patients.Type: ApplicationFiled: May 23, 2014Publication date: November 20, 2014Applicant: WARSAW ORTHOPEDIC, INC.Inventors: William F. McKay, Steven Marquis Peckham, Jeffrey L. Seifert
-
Publication number: 20140336595Abstract: The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-? superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.Type: ApplicationFiled: February 21, 2014Publication date: November 13, 2014Applicant: STRYKER CORPORATIONInventors: Mary Elizabeth Pecquet Goad, Melissa M. Haskell, Denis Schrier, Susan A. Wood
-
Publication number: 20140336114Abstract: The present invention provides formulations of cysteine knot proteins, including TGF-? superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-? superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation.Type: ApplicationFiled: November 25, 2013Publication date: November 13, 2014Applicant: STRYKER CORPORATIONInventors: David D. Hile, Gregg Strohmeier
-
Publication number: 20140335155Abstract: The present invention provides a composition for improving skin conditions, containing the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient. The present invention contains the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient inside a nanoliposome comprising hydrogenated lecithin as a constituent component, and the particle size is 50-250 nm. The composition of the present invention reduces wrinkles and alleviates atopic dermatitis. In addition, the present invention provides a method for improving skin conditions, comprising the step of administering a composition containing the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient to a subject.Type: ApplicationFiled: August 30, 2012Publication date: November 13, 2014Applicant: JOINT CENTER FOR BIOSCEINCESInventors: Zung Yoon Yang, Byung Hak Yoon, Seung-Hyon Choi
-
Publication number: 20140335145Abstract: The invention provides products of manufacture, e.g., biomaterials and implants, for cartilage maintenance and/or formation in-vivo, in-vitro, and ex-vivo, using nanotechnology, e.g., using nanotube, nanowire, nanopillar and/or nanodepots configured on surface structures of the products of manufacture.Type: ApplicationFiled: July 27, 2014Publication date: November 13, 2014Inventors: Sungho JIN, Seunghan OH, Karla BRAMMER
-
Patent number: 8883725Abstract: The present invention relates to compositions and methods useful in studying or modulating melanin pigmentation in the skin. Particularly, the invention relates to compositions comprising a substance capable of modulating the activity or expression of ALK6 (SEQ ID 2) or Cdc42 which in turn are capable of modulation of the transfer of melanin from melanocytes to keratinocytes and potentially from keratinocytes to keratinocytes. The invention also relates to assays for identifying such compositions, and methods of modulating skin pigmentation.Type: GrantFiled: September 8, 2009Date of Patent: November 11, 2014Assignee: University of BradfordInventors: Suman Kumar Singh, Desmond John Tobin
-
Patent number: 8883184Abstract: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.Type: GrantFiled: January 20, 2009Date of Patent: November 11, 2014Assignee: Pioneer Surgical Technology, Inc.Inventors: Ronald Stewart Hill, Richard Chris Klann, Francis V. Lamberti
-
Patent number: 8883728Abstract: Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.Type: GrantFiled: November 24, 2010Date of Patent: November 11, 2014Assignee: Aegis Therapeutics, LLCInventor: Edward T. Maggio
-
Publication number: 20140322292Abstract: Methods of promoting bone healing or regeneration by locally administering insulin mimetic agents to patients in need thereof and new uses of insulin-mimetic compounds for accelerating bone-healing processes are disclosed. Bone injury treatment and void filler devices, products and kit suitable for local administration of insulin-mimetic agents or compositions thereof to patients in need of such treatment are also disclosed.Type: ApplicationFiled: November 29, 2012Publication date: October 30, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Sheldon S. Lin, David N. Paglia, James P. O'Connor, Joseph Benevenia, Aaron Wey, Sangeeta Subramanian, John D. Koerner
-
Patent number: 8871710Abstract: This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. The compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The compositions can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.Type: GrantFiled: December 20, 2012Date of Patent: October 28, 2014Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Jens Pohl, Frank Ploeger
-
Publication number: 20140315807Abstract: The invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolving. In particular, the inventive methods may be useful for treating or preventing conditions associated with bone degradation, deterioration or degeneration such as periodontal disease, osteoarthritis, and metastatic bone disease and osteolytic bone disease. Pharmaceutical compositions and kits comprising at least one resolving are also provided that can be used to performed the inventive methods.Type: ApplicationFiled: December 19, 2013Publication date: October 23, 2014Applicant: The Forsyth InstituteInventor: Thomas E. Van Dyke
-
Publication number: 20140302111Abstract: Provided is a method for regenerating dental tissue, which can include contacting a scaffold containing Wnt3a and BMP-7, and optionally VEGF, bFGF, or NGF, with a dental tissue so as to promote odontoblastic differentiation of a progenitor cell, promote progenitor cell migration into the dental tissue, or regenerate the dental tissue. Also provided is a composition for regeneration of dental tissue, which can include a scaffold and Wnt3a and BMP-7, and optionally VEGF, bFGF, or NGF.Type: ApplicationFiled: March 21, 2014Publication date: October 9, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jeremy J. Mao, Ying Zheng, Guoming Sun, Songlin Wang
-
Publication number: 20140302129Abstract: Human lubricating gels, methods and kits for delivering a therapeutic agent to a target tissue site beneath the skin of a patient utilizing human lubricating gel are provided, the human lubricating gel being capable of adhering to the target tissue site and comprising one or more biodegradable formulations containing an effective amount of the therapeutic agent. In various embodiments, the human lubricating gel is sprayable and hardens after contacting the target tissue site.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventors: Susan J. Drapeau, Guobao Wei
-
Publication number: 20140294783Abstract: Inventive concepts relate general to the field of implantable three-dimensional scaffolds. More particularly, methods of preparing and using implantable nanofibrous tissue scaffolds are described. Inventive scaffolds can be used for treatment of defects in a living organism, such as hard or soft tissue defects including bone.Type: ApplicationFiled: October 11, 2012Publication date: October 2, 2014Inventors: Jie Wen, Nell Herrera Wirth, Patrick E. Guire
-
Publication number: 20140271471Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminoglycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Genzyme CorporationInventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
-
Publication number: 20140271779Abstract: Synthetic, bioactive ultra-porous bone graft materials having an engineered porosity, and implants formed from such materials are provided. In particular, these implants comprise bioactive glass and incorporate allograft material for osteoinduction. The implants are suitable for bone tissue regeneration and/or repair.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: PROSIDYAN, INC.Inventors: Charanpreet S. BAGGA, Steve B. JUNG, Hyun W. BAE
-
Patent number: 8835384Abstract: This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue.Type: GrantFiled: May 20, 2009Date of Patent: September 16, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: Andre Terzic, Atta Behfar
-
Patent number: 8828946Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.Type: GrantFiled: December 10, 2010Date of Patent: September 9, 2014Assignee: Orthogen AGInventors: Peter Wehling, Julio Reinecke
-
Patent number: 8828937Abstract: The present invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1, characterized in that said amino acid sequence comprises at least two amino acid substitutions characterized in that a first amino acid substitution occurs at a position corresponding to N59, S88, E94, V99, K101 and/or N102 of SEQ ID No. 1 and to uses thereof.Type: GrantFiled: March 11, 2010Date of Patent: September 9, 2014Assignee: Haase Investments UGInventors: Petra Seemann, Stefan Mundlos, Carsten Reissner, Georg Duda, Julia Zimmer
-
Patent number: 8828941Abstract: The present invention provides compositions of matter suitable for the prevention of and/or treatment of a spinal disorder and/or spinal pain, e.g., caused by and/or associated with intervertebral disc (IVD) degeneration, and methods of treatment of a spinal disorder and/or spinal pain. For example, the compositions of the present invention comprise a modulator of growth differentiation factor (GDF)-6 signaling sufficient to reduce or prevent or delay IVD degeneration and/or to enhance or induce IVD regeneration. The present invention also provides medical devices comprising such compositions, and methods of treatment making use of such compositions.Type: GrantFiled: February 22, 2008Date of Patent: September 9, 2014Inventors: Ashish Diwan, Divya Diwan
-
Publication number: 20140248372Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes.Type: ApplicationFiled: September 17, 2012Publication date: September 4, 2014Applicant: EMORY UNIVERSITYInventors: Scott D. Boden, Sreedhara Sangadala
-
Publication number: 20140242044Abstract: An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery. Additionally, the implant may include, or have blended in, an additive, such as an osteoinductive factor, for example biocompatible ceramics and glass.Type: ApplicationFiled: May 6, 2014Publication date: August 28, 2014Applicant: Kensey Nash BVF Technology LLCInventors: Douglas G. EVANS, Scott M. Goldman, Russell T. Kronengold
-
Patent number: 8815800Abstract: The invention is directed to skin moisturizing compositions comprising an aminopeptide mixture. The composition replenishes the skins natural moisturization factor and delivers excellent sensory benefits. The composition is not unpleasantly viscous during and after application.Type: GrantFiled: November 29, 2012Date of Patent: August 26, 2014Assignee: Conopco, Inc.Inventors: Eugene Pashkovski, Tamara Litvin, Alexander Lips
-
Publication number: 20140236299Abstract: Synthetic composite materials for use, for example, as orthopedic implants are described herein. In one example, a composite material for use as a scaffold includes a thermoplastic polymer forming a porous matrix that has continuous porosity and a plurality of pores. The porosity and the size of the pores are selectively formed during synthesis of the composite material. The example composite material also includes a plurality of a anisometric calcium phosphate particles integrally formed, embedded in, or exposed on a surface of the porous matrix. The calcium phosphate particles provide one or more of reinforcement, bioactivity, or bioresorption.Type: ApplicationFiled: November 13, 2013Publication date: August 21, 2014Inventors: Ryan K. Roeder, Gabriel L. Converse, Stephen M. Smith
-
Publication number: 20140227254Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.Type: ApplicationFiled: December 27, 2013Publication date: August 14, 2014Applicant: Acceleron Pharma, Inc.Inventors: Jasbir Seehra, John Knopf, Robert S. Pearsall, Asya Grinberg, Ravindra Kumar
-
Publication number: 20140227219Abstract: In an aspect, the invention relates to compositions comprising BMP-7 and methods of using disclosed compositions. In an aspect, the invention relates to compositions for and methods of treating atherosclerosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: February 8, 2014Publication date: August 14, 2014Applicant: University of Central Florida Research Foundation, Inc.Inventor: Dinender Singla
-
Patent number: 8802123Abstract: Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.Type: GrantFiled: June 8, 2012Date of Patent: August 12, 2014Assignees: Universite de Geneve, Ecole Polytechnique Federale de LausanneInventors: Pierre Descouts, Björn-Owe Aronsson, Michael Grätzel, Carine Viornery, Peter Péchy
-
Patent number: 8802626Abstract: Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and detects resulting from degenerative diseases such as osteochondritis dessicans.Type: GrantFiled: March 18, 2011Date of Patent: August 12, 2014Assignee: Stryker CorporationInventors: David C. Rueger, Marjorie M. Tucker, An-Cheng Chang
-
Publication number: 20140220085Abstract: In an embodiment of the disclosure, a biomedical material is provided. The biomedical material includes a biocompatible material having a surface and a carrier distributed over the surface of the biocompatible material, wherein both of the biocompatible material and the carrier have no charges, one of them has charges or both of them have charges with different electricity. The biomedical material is utilized for dentistry, orthopedics, wound healing or medical beauty and applied in the repair and regeneration of various soft and hard tissues.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: Industrial Technology Research InstituteInventors: Pei-Yi TSAI, Yi-Hung WEN, Zhi-Jie HUANG, Pei-Shan LI, Hsin-Hsin SHEN, Yi-Hung LIN, Chih-Hung CHEN
-
Publication number: 20140219953Abstract: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.Type: ApplicationFiled: January 2, 2014Publication date: August 7, 2014Applicants: Excel Med, LLC, National Cheng Kung UniversityInventor: Lynn L.H. Huang
-
Patent number: 8796208Abstract: Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a columnar growth promoting agent.Type: GrantFiled: February 21, 2012Date of Patent: August 5, 2014Assignee: Genera Istrazivanja d.o.o.Inventors: Slobodan Vukicevic, Mislav Jelic
-
Patent number: 8796212Abstract: A composition comprising a synthetic growth factor analog comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analog is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: GrantFiled: July 19, 2011Date of Patent: August 5, 2014Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena
-
Patent number: 8785383Abstract: The present invention is directed to methods of treating or preventing the development of obesity by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing obesity.Type: GrantFiled: April 15, 2013Date of Patent: July 22, 2014Assignee: The Brigham and Women's Hospital, Inc.Inventor: Guo-Ping Shi
-
Publication number: 20140199322Abstract: The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.Type: ApplicationFiled: March 20, 2014Publication date: July 17, 2014Applicant: DePuy Synthes Products, LLCInventors: Mohamed Attawia, Thomas M. DiMauro, Hassan Serhan, Sudhakar Kadiyala, David Urbahns, Scott Bruder
-
Publication number: 20140200182Abstract: The present invention relates to compositions of bone morphogenetic proteins, particularly solid and liquid formulations of such proteins comprising one or more stabilizing excipients. The invention further provides methods of producing the compositions, kits comprising the compositions and methods of using the compositions in the treatment of diseases of skeletal and non-skeletal tissues.Type: ApplicationFiled: August 20, 2013Publication date: July 17, 2014Applicant: Stryker CorporationInventor: Niles Ron
-
Patent number: 8778869Abstract: A system for growing tissue based upon layers of an inorganic extracellular matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution.Type: GrantFiled: June 9, 2010Date of Patent: July 15, 2014Assignee: Wisconsin Alumni Research FoundationInventors: William L. Murphy, Mark D. Markel, Ben K. Graf, Yan Lu, Jae Sung Lee
-
Publication number: 20140193425Abstract: Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALK1) antagonist are provided. Methods for selecting a subject for treatment with an ALK1 antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic methods provided herein are based on detecting an ALK1 agonist, e.g., an ALK1 ligand such as BMP9 or BMP10, in a sample obtained from the subject. Diagnostic reagents and kits for determining whether a subject is responsive to treatment with an ALK1 antagonist are also provided.Type: ApplicationFiled: October 4, 2013Publication date: July 10, 2014Applicant: Acceleron Pharma, Inc.Inventors: John Knopf, Ravindra Kumar, Robert S. Pearsall, Matthew L. Sherman
-
Patent number: 8772234Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.Type: GrantFiled: April 9, 2012Date of Patent: July 8, 2014Assignee: Acceleron Pharma, Inc.Inventors: Jasbir Seehra, John Knopf
-
Publication number: 20140187486Abstract: The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-? superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.Type: ApplicationFiled: July 18, 2013Publication date: July 3, 2014Applicant: Stryker CorporationInventors: Mary Elizabeth Pecquet Goad, Melissa M. Haskell, Denis Schrier, Susan A. Wood
-
Publication number: 20140187473Abstract: The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-? superfamily. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.Type: ApplicationFiled: August 7, 2013Publication date: July 3, 2014Applicant: Stryker CorporationInventors: Mary Elizabeth Pecquet Goad, Denis Schrier, Allen Richard Pierce
-
Publication number: 20140178455Abstract: The present invention provides gradient porous scaffolds for bone regeneration and osteochondral defect repair, methods for making such gradient porous scaffolds, and methods for using the gradient porous scaffolds.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Inventors: Syam P. Nukavarapu, Cato T. Laurencin, Ami R. Amini, Deborah L. Dorcemus
-
Patent number: 8759296Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: May 25, 2012Date of Patent: June 24, 2014Assignees: The Regents of The University of California, The United States of America as Represented by The Department of Veterans AffairsInventors: Samuel S. Murray, Keyvan Behnam, Elsa J. Brochmann-Murray
-
Patent number: 8758791Abstract: A highly compression resistant matrix is provided for implantation at or near a target tissue site beneath the skin. The matrix comprises a polymer and a ceramic skeleton. The compression resistance provides retention of a volume that facilitates bone regeneration.Type: GrantFiled: January 26, 2010Date of Patent: June 24, 2014Assignee: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20140171367Abstract: Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.Type: ApplicationFiled: March 19, 2012Publication date: June 19, 2014Applicant: GEORGIA TECH RESEARCH CORPORATIONInventors: Niren Murthy, Christopher Hermann, David Scott Wilson, Xinghai Ning, Barbara D. Boyan, Zvi Schwartz, Robert Guldberg, Tamim Diab
-
Patent number: 8748378Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.Type: GrantFiled: April 4, 2011Date of Patent: June 10, 2014Assignee: Stryker CorporationInventors: Charles M. Cohen, Kuber T. Sampath, Slobodan Vukicevic